TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01427933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1121B)
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administered intravenously
Study: NCT02770989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vimecon Laser CAI percutaneous cardiac ablation
Description: The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
Study: NCT01431781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stilamin+common daily treatment
Description: dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Common daily practice
Description: Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
Study: NCT01053988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF Inhalation Powder
Description: Inhaled Corticosteroid (ICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 Inhalation Powder
Description: Long Acting Beta Agonist(LABA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02904733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth platform
Description: Use of a mHealth platform to inform and empower patient of hies/her own health
Study: NCT02287428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrent Temozolomide (TMZ) = 75 mg/m2/day for 6 weeks, administered with XRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Adjuvant Temozolomide (TMZ) = 150 mg/m2/day on days 1-5 of each 28-day cycle for up to 6 adjuvant cycles
Study: NCT01258803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate DPI
Description: Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate DPI
Description: Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate DPI
Description: Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate DPI
Description: Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study: NCT02287428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
Study: NCT02388737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules or tablets
Study: NCT01258803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study: NCT01258803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Study: NCT02388737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan Placebo
Description: Vonoprazan placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Placebo
Description: Vonoprazan placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Placebo
Description: Vonoprazan placebo-matching tablets
Study: NCT02889861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100
Description: Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
Study: NCT03831282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET Neo SpO2
Description: All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
Study: NCT00429546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching, Raising, and Communicating with Kids (TRACK)
Description: TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual includes standard care for HIV infected mothers.
Study: NCT01451203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CZP
Description: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate (MTX)
Description: oral
Study: NCT04441619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed onset muscle soreness.
Description: Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
Study: NCT04981652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Milk
Description: Participants will consume twice daily whole milk beverages in addition to a standardized diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: Participants will consume twice daily skim milk beverages in addition to a standardized diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond Beverage
Description: Participants will consume twice daily almond beverages in addition to a standardized diet.
Study: NCT03948841

Intervention type: OTHER
Intervention: magnetic resonance imaging
Study: NCT04322617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus the same Immune Checkpoint Inhibitors.
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus the new Immune Checkpoint Inhibitors.
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.
Study: NCT00959595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: 50g applied according to description of intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EMLA cream
Description: 50g applied according to description of intervention
Study: NCT01894932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive Group therapy
Description: In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive Group therapy
Description: In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-physiological stress regulation group
Description: Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-physiological stress regulation group
Description: Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
Study: NCT02000297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogenic bone graft
Description: Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synthetic bone substitute (geneX®)
Description: Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
Study: NCT01856582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+
Description: CD34+ cells are selected using the CliniMACS System; without preparative regimen
Study: NCT03276897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)
Description: A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
Study: NCT01379196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Tab. Azithromycin 500 mg PO three times weekly for 3 months
Study: NCT03700567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low temperature contrast
Description: UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
Study: NCT04362423

Intervention type: DEVICE
Intervention: fNIRS
Description: Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.

Intervention type: DEVICE
Intervention: fNIRS
Description: Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.

Intervention type: DEVICE
Intervention: fNIRS
Description: Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.
Study: NCT01546662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E-RH-06
Description: Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E-RH-06
Description: Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/ 2 capsules, twice daily for 12 weeks
Study: NCT03203083

Intervention type: OTHER
Intervention: performance of the single leg squat task
Description: The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.

Intervention type: OTHER
Intervention: performance of the single leg squat task
Description: The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
Study: NCT03009734

Intervention type: DRUG
Group type: OTHER
Intervention: ATx201 dermal formulations 2%
Description: Topical application of ATx201 dermal formulations 2%

Intervention type: DRUG
Group type: OTHER
Intervention: ATx201 dermal formulations 2%
Description: Topical application of ATx201 dermal formulations 2%
Study: NCT02388737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules
Study: NCT03055000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v
Description: AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v + adjuvant
Description: ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: WFI (0.5mL) on Day 0 and Day 21
Study: NCT02423616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy individuals
Description: INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
Study: NCT04408846

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumbar fusion
Description: Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumbar fusion
Description: Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
Study: NCT02409836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Dentifrice
Description: Marketed Dentifrice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Flavored Dentifrice
Description: Hawaiian Punch Flavored

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Flavored Dentifrice
Description: Bubble Gum Flavored
Study: NCT01538693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram oxalate
Description: 10 mg 4.5 hours prior to testing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: 8mg 4.5 hours prior to testing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: 4.5 hour prior to testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded intensity exercise
Description: modified bruce protocol for peak oxygen consumption testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded intensity exercise
Description: modified bruce protocol for peak oxygen consumption testing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Graded intensity exercise
Description: modified bruce protocol for peak oxygen consumption testing
Study: NCT02259153

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changes in cholesterol metabolism

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changes in cholesterol metabolism

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lean red meat diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat red meat diet
Study: NCT04092166

Intervention type: OTHER
Group type: OTHER
Intervention: Stationary Bike
Description: Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
Study: NCT03250546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant from a haplo-identical donor
Description: The transplant procedures will be similar in the 2 groups beside the origin of cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transplant from a non related donor
Description: The transplant procedures will be similar in the 2 groups beside the origin of cells
Study: NCT03941535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
Study: NCT02287428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
Study: NCT01669291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bravelle and Menopur
Description: Bravelle and Menopur are used for controlled ovarian stimulation (COH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bravelle and Menopur
Description: Bravelle and Menopur are used for controlled ovarian stimulation (COH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist
Description: Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
Study: NCT03774069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical guided recommendation
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
Study: NCT02764229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-30937-EC
Description: LYC-30937-EC 25 mg by mouth once daily